AR002968A1 - Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica. - Google Patents

Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica.

Info

Publication number
AR002968A1
AR002968A1 ARP960101719A AR10171996A AR002968A1 AR 002968 A1 AR002968 A1 AR 002968A1 AR P960101719 A ARP960101719 A AR P960101719A AR 10171996 A AR10171996 A AR 10171996A AR 002968 A1 AR002968 A1 AR 002968A1
Authority
AR
Argentina
Prior art keywords
treatment
preparation
pharmaceutical composition
acute
infarction
Prior art date
Application number
ARP960101719A
Other languages
English (en)
Original Assignee
Behringwerke Ag
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag, Brigham & Womens Hospital filed Critical Behringwerke Ag
Publication of AR002968A1 publication Critical patent/AR002968A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El invento se refiere al uso de la combinación de hirudina y ácido acetilsalicílico (ASA) a pacientes que no están siendo sometidos a tramientocon ningún agente trombolítico, inhibe y/o evita los sucesos miocárdicos o cardiovasculares en el paciente para la preparación de un medicamento. Elinvento se refiere además a la combinación farmacéutica de un fármaco inactivador de plaquetas, ácido acetilsalicílico, y un inhibidor de trombinadirecto, hirudina, para el tratamientode pacientes con infarto de miocardio agudo, que no están siendo sometidos a trombólisis. Una composiciónfarmacéutica que comprende la combinación sinérgica de hirudina y ASA, en ausencia de cualquier agente trombolítico, es particularmenteútil en losmétodos terapéuticos y profilácticos del invento.
ARP960101719A 1995-03-15 1996-03-12 Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica. AR002968A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40526995A 1995-03-15 1995-03-15
US44055695A 1995-05-12 1995-05-12

Publications (1)

Publication Number Publication Date
AR002968A1 true AR002968A1 (es) 1998-05-27

Family

ID=27019016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101719A AR002968A1 (es) 1995-03-15 1996-03-12 Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica.

Country Status (14)

Country Link
EP (1) EP0732102A3 (es)
JP (1) JPH0920681A (es)
KR (1) KR960033468A (es)
CN (1) CN1141809A (es)
AR (1) AR002968A1 (es)
AU (1) AU711660B2 (es)
BR (1) BR9601024A (es)
CA (1) CA2171509A1 (es)
FI (1) FI961171A (es)
IL (1) IL117485A0 (es)
NO (1) NO961046L (es)
NZ (1) NZ286082A (es)
SG (1) SG43242A1 (es)
UY (1) UY24181A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004262776A (ja) * 2003-02-21 2004-09-24 Teikoku Seiyaku Co Ltd 血管新生促進剤
WO2005027896A1 (ja) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. 併用医薬
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field

Also Published As

Publication number Publication date
KR960033468A (ko) 1996-10-22
UY24181A1 (es) 1996-03-20
EP0732102A3 (en) 1999-01-27
CA2171509A1 (en) 1996-09-16
AU711660B2 (en) 1999-10-21
NO961046L (no) 1996-09-16
NZ286082A (en) 1998-09-24
CN1141809A (zh) 1997-02-05
SG43242A1 (en) 1997-10-17
FI961171A0 (fi) 1996-03-13
AU4807296A (en) 1996-09-26
FI961171A (fi) 1996-09-16
IL117485A0 (en) 1996-07-23
NO961046D0 (no) 1996-03-14
EP0732102A2 (en) 1996-09-18
JPH0920681A (ja) 1997-01-21
BR9601024A (pt) 1997-12-30

Similar Documents

Publication Publication Date Title
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
Smith Drug treatment of varicose veins, venous edema, and ulcers
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
HUP9902889A2 (hu) 3-Fenil-4-(4-metilszulfonil)-fenil-2-(5H)-furanon alkalmazása gyulladáscsökkentő gyógyszerkészítmény előállítására, és az ilyen készítmények
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ES2188663T3 (es) Uso de productos que contienen magnesio para el tratamiento o profilaxis de enfermedades neoplasicas o autoinmunes.
ES2126123T3 (es) Empleo de cineol o mentol para el tratamiento de asma.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ATE193651T1 (de) Therapeutisches system zur behandlung der psoriasis
AR002968A1 (es) Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica.
ES2145803T3 (es) Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades.
KR910005858A (ko) 지방산 요법
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
GR3017855T3 (en) Use of lithium in the treatment or prophylaxis of Molluscum contagiosum.
Gertner Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
MX9307479A (es) Uso de ciertos derivados de acido metanobisfosfonico en la curacion de fracturas.
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose